REG - RTW Biotech Opp. - Notice of AGM

RTW Biotech OpportunitiesAnnouncement

16/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250516:nRSP9021Ia&default-theme=true

RNS Number : 9021I  RTW Biotech Opportunities Ltd  16 May 2025

LEI: 549300Q7EXQQH6KF7Z84

16 May 2025

RTW Biotech Opportunities Ltd
(the "Company")

Notice of Annual General Meeting

RTW Biotech Opportunities Ltd announces that its Annual General Meeting
("AGM") will be held at 1(st) Floor Royal Chambers, St Julian's Avenue St
Peter Port, Guernsey on 9 June 2025 at 2pm BST. The Notice of AGM was
dispatched to all shareholders on 15 May 2025.

A copy of the Notice of AGM has been submitted to the National Storage
Mechanism and will shortly be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) The Notice of AGM may
also be viewed on the Company's website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)

The Annual Report and Audited Financial Statements for the year ended 31
December 2024 (the "Annual Report") is also available on the Company's
website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(http://www.rtwfunds.com/rtw-biotech-opportunities-ltd)

You will not have received a hard copy proxy form for the AGM in the post. You
can instead submit your proxy vote electronically via the Investor Centre app
or by accessing the web browser at https://uk.investorcentre.mpms.mufg.com/
(https://uk.investorcentre.mpms.mufg.com/) . Full details of how to vote are
set out in the Notes to the Notice of Meeting. Please submit your proxy vote
so as to reach the Company's registrar as soon as possible and in any event no
later than 2pm BST on 5 June 2025 or, if you are a CREST member, by using the
service provided by Euroclear. Shares held on your behalf by a broker or
nominee must be voted by the broker, per your instructions, and cannot be
voted at https://uk.investorcentre.mpms.mufg.com/. The completion of the form
of proxy will not preclude a member from attending and voting in person at the
meeting if it is so allowed.

If any shareholder has questions related to the business of the AGM, please
submit your queries to biotechopportunities@rtwfunds.com
(mailto:biotechopportunities@rtwfunds.com) by 2pm BST on 5 June 2025.

 

Enquiries:

 RTW Investments, LP - Investment Manager               +44 (0)20 7959 6361

 Woody Stileman (Business Development)                  biotechopportunities@rtwfunds.com

 Oliver Kenyon (Business & Corporate Development)

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                                        +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)                            +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker                +44 (0)20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Euan Brown

 BofA Securities - Joint Corporate Broker               +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                               +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(http://www.rtwfunds.com/rtw-biotech-opportunities-ltd)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAEASSSFSLSEFA